Somatic mutations of epidermal growth factor receptor (EGFR) gene are detected in almost 50% of East Asian NSCLC cases and have attracted significant attention in the realm of targeted therapy (Hirsch et al., 2003; Krause and Van Etten, 2005; Nicholson et al., 2001; Passaro et al., 2021a). Here, EGFR is linked to non-small cell lung carcinoma.